Clinical Practice of Poly (ADP‐Ribose) Polymerase Inhibitors for Maintenance Treatment of Platinum‐Sensitive Recurrent Ovarian Cancer in China

ABSTRACT Clinical trials of three poly (ADP‐ribose) polymerase (PARP) inhibitors, olaparib, niraparib and fuzuloparib, in platinum‐sensitive recurrent ovarian cancer (PSR OC) in China showed that PARP inhibitors improved progression‐free survival and achieved an all‐comer indication in this population. We reviewed the efficacy and safety of these PARP inhibitors in patient populations studied in clinical trials and highlighted the positive role of PARP inhibitors in improving patient outcomes using clinical trials and real‐world studies conducted in China. This article also discusses the issues encountered in clinical practice and how to evaluate the different indications for PSR OC in China and abroad.